NR1I2 and hepatocellular carcinoma: By using the HepG2 human liver carcinoma cell line stably expressing hPXR and a luciferase reporter under the control of the promoter of CYP3A427, a transcriptional target of hPXR, we screened a library of 160,000 chemically diverse compounds in the presence of rifampicin, an hPXR agonist and identified a number of hPXR antagonists, including SJ000076745-1, the most potent hPXR antagonist identified from the screen (Lin et al., in submission), which we call SPA70 (specific PXR antagonist #70, also known as LC-1) (Supplementary Table 1).